HONG KONG – South Korean bioinformatics company Syntekabio Inc. pocketed $11.2 million in a series B financing to advance two of it core platforms in bioinformatics and AI-driven drug discovery to speed up drug development process. Read More
HONG KONG – Denmark's Novo Nordisk A/S has teamed up with Singapore's Duke-NUS Medical School to provide funding for the next three to five years for stem cell-based research aimed at growing heart muscle and retinal cells to treat heart failure and vision loss. Read More
HONG KONG – China's Chia Tai Tianqing Pharmaceutical Holdings Co. Ltd. gained marketing approval for its first innovative treatment for advanced non-small-cell lung cancer (NSCLC), which has the potential of becoming a standard third-line treatment for the disease. Read More
Splendris International Ltd., of Shenzhen, China, an affiliate of Shenzhen Salubris Pharmaceuticals Co. Ltd., inked an investment and in-licensing agreement with Swiss firm Medalliance SA under which Salubris will make a $20 million equity investment in Medalliance and will commit an additional $10 million in development milestones in exchange for exclusive rights to develop and commercialize Medalliance's lead product, Selution, a sirolimus micro-reservoir drug-coated balloon, for peripheral and cardiovascular applications in the Chinese market. Read More
HONG KONG – Chugai Pharmaceutical Co. Ltd., of Tokyo, said its Alecensa (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, gained expanded approved as a first-line treatment for ALK-positive non-small-cell lung cancer (NSCLC) in Taiwan. Read More
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, appointed Fumihiro Nishi senior director, internal auditing and Tomokazu Nagano senior director, external affairs; corporate secretariat and industry affairs. Read More
As Zymeworks Inc. prepares to unveil new phase I data from its lead bispecific antibody candidate at the upcoming American Society of Clinical Oncology meeting, its platform technology scored another win in the validation column. Less than two years after licensing rights to Zymeworks' Azymetric and EFECT technology platforms to develop one bispecific candidate, Daiichi Sankyo Co. Ltd. returned to the negotiating table for more. Read More
